HALO - ハロザイム・セラピュ―ティクス （Halozyme Therapeutics Inc.） ハロザイム・セラピュ―ティクスHALOのチャート
HALOの企業情報
| symbol | HALO |
|---|---|
| 会社名 | Halozyme Therapeutics Inc （ハロザイム・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ハロザイム・セラピューティクス（Halozyme Therapeutics Inc.）は腫瘍学療法の開発と商業化を行うバイオ医薬品会社である。同社はヒトの酵素および他の候補薬剤の研究、開発、および商業化を行う。同社のセグメントには研究・開発活動およびHylenex組換え品の製品・販売を含む。同社の開発パイプラインは腫瘍学における臨床段階の製品候補を含む。リード腫瘍学プログラムはHAを蓄積する腫瘍の全身治療のために開発された分子実体であるPEGPH20（ポリエチレングリコール（PEG）イル化組換えヒトヒアルロニダーゼ）である。同社はステージIVの膵管腺癌（試験109-202および109-301）におけるPEGPH20の第II相および第III相臨床試験、非小細胞肺癌におけるフェーズIb臨床試験（試験107-201）、および非小細胞肺癌および胃癌におけるフェーズIb臨床試験（試験107-101）にある。 ハロザイム・セラピュ―ティクスは、米国のバイオ医薬品会社。細胞外マトリックスを変更するヒト酵素の研究に基づき、糖尿病、癌、皮膚病治療用の薬品を開発。同社の承認された製品や製品候補は、特許を取得した遺伝子組換え型ヒトヒアルロニダ―ゼ酵素「rHuPH20」をベ―スとしている。主要製品は、「Hylenex」「超高速インスリンプログラム」など。 we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies |
| 本社所在地 | 11388 Sorrento Valley Road San Diego CA 92121 USA |
| 代表者氏名 | Connie L. Matsui コニー・マツイ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 858-794-8889 |
| 設立年月日 | 1998年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 255人 |
| url | www.halozyme.com |
| nasdaq_url | https://www.nasdaq.com/symbol/halo |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 92.39600 |
| 終値（lastsale） | 17.53 |
| 時価総額（marketcap） | 2529653327.2 |
| 時価総額 | 時価総額（百万ドル） 2360.817 |
| 売上高 | 売上高（百万ドル） 319.36900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2127.968 |
| 当期純利益 | 当期純利益（百万ドル） 76.27700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Halozyme Therapeutics Inc. revenues increased 4% to $66.1M. Net loss decreased 21% to $50.4M. Revenues reflect Royalties increase of 43% to $40.9M Revenues under collaborative agreements increase of 33% to $13.9M. Lower net loss reflects Investment and other income increase from $722K to $3.7M (income) Interest expense decrease of 9% to $10M (expense). |
HALOのテクニカル分析
HALOのニュース
Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference 2023/06/06 12:30:00 PR Newswire
SAN DIEGO, June 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023, at 8 a.m. PT…
Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure 2023/05/27 19:33:00 Kwhen Finance
7 Meme Stocks to Buy Before They Soar to New Heights in 2023 2023/05/25 20:15:33 InvestorPlace
Memes are simply images and videos with humorous text included that tend to spread rapidly across the internet. Combine them with stocks and you get wallstreetbets . That’s where the majority of meme stock information is communicated. For an easier-to-navigate listing of meme stocks investors can go here . That’s where all of the companies discussed below were found. These shares are not risky overall despite the reputation that investing in meme stocks may have. There are a few bets to be sure. But those are substantiated using the reasoning of the commenters which is logical. That said, let’s get into those meme-worthy and investment-grade shares. Nvidia (NVDA) Source: Michael Vi / Shutterstock.com When investing in meme stocks, Nvidia (NASDAQ: NVDA ) is far and away the most talked about stock on memestocks.org. It also happens to be a highly respected firm with a lot of positives worth understanding. Meme stocks have a reputation for being risky. Nvidia, despite being one of the largest companies globally, is certainly risky, too.
Here’s Why Halozyme Therapeutics (HALO) Declined in Q1 2023/05/22 07:26:02 Insider Monkey
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. In the first quarter, its Investor Class fund ARTSX returned 7.60%, Advisor Class fund APDSX posted a return of 7.63%, and Institutional Class fund APHSX returned 7.62%, compared to a […]
Thursday’s Top Analyst Upgrades and Downgrades: Airbnb, Antero Midstream, Exact Sciences, GitLab, Lumentum, Nektar Therapeutics, PayPal and More 2023/05/11 12:52:04 24/7 Wall street
Thursday''s top analyst upgrades and downgrades included Airbnb, Alcon, Antero Midstream, Exact Sciences, GitLab, GlobalFoundries, Halozyme Therapeutics, Lumentum, Nektar Therapeutics, PayPal and Southern Copper.
Halozyme to Report Third Quarter 2022 Financial and Operating Results 2022/10/25 12:30:00 PR Newswire
SAN DIEGO, Oct. 25, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2022 financial and operating results on Tuesday, November 8, 2022, following the close of trading. Halozyme will host a conference call on…
Halozyme Looks Good For Their Excellent Royalty Revenue Stream 2022/10/24 12:00:00 Seeking Alpha
Halozyme made a smooth transition from a failed R&D company to a successful royalty company. For the next few years, HALO is on a growth trajectory. Read more here.
Halozyme Therapeutics: A Pharma Mutual Fund In A Single Company (NASDAQ:HALO) 2022/10/24 09:45:08 Seeking Alpha
Halozyme Therapeutics is well fixed to grow revenues from multiple sources over the balance of this decade and beyond. See why I view HALO as a definite buy.
Investing in Halozyme Therapeutics Inc. (HALO) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/09/15 11:16:00 US Post News
Halozyme Therapeutics Inc. (NASDAQ:HALO) marked $42.51 per share on Wednesday, up from a previous closing price of $41.30. While Halozyme Therapeutics Inc. has overperformed by 2.93%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HALO rose by 2.68%, with highs and lows ranging from $52.98 to […]
Halozyme Therapeutics Inc. (NASDAQ: HALO): Still A Hot Buy? 2022/08/16 17:00:00 Stocks Register
Halozyme Therapeutics Inc. (NASDAQ:HALO) price is hovering higher on Tuesday, August 16, jumping 0.44% above its previous close. A look at today’s price movement shows that the recent level at last check reads $43.09, with intraday deals fluctuating between $41.81 and $43.58. The company’s 5Y monthly beta was ticking 1.20 while its P/E ratio in … Halozyme Therapeutics Inc. (NASDAQ: HALO): Still A Hot Buy? Read More »
Halozyme Therapeutics Inc. (NASDAQ: HALO): Still A Hot Buy? 2022/08/16 17:00:00 Stocks Register
Halozyme Therapeutics Inc. (NASDAQ:HALO) price is hovering higher on Tuesday, August 16, jumping 0.44% above its previous close. A look at today’s price movement shows that the recent level at last check reads $43.09, with intraday deals fluctuating between $41.81 and $43.58. The company’s 5Y monthly beta was ticking 1.20 while its P/E ratio in … Halozyme Therapeutics Inc. (NASDAQ: HALO): Still A Hot Buy? Read More »
Halozyme Therapeutics raises $625M through convertible senior notes due 2028 2022/08/16 09:40:49 Seeking Alpha
Halozyme Therapeutics (HALO) has priced upsized offering of $625M of 1.00% convertible senior unsecured notes due August 15, 2028.The offering was upsized from an originally…
Halozyme Therapeutics Shares Jump On Better Than Expected Annual Guidance 2022/08/10 11:48:53 Benzinga
Halozyme Therapeutics Inc (NASDAQ: HALO ) reported Q2 revenue of $152.4 million , +12% Y/Y, surpassing the consensus of $138.78 million. The increase was primarily driven by an increase in royalty revenue primarily attributable to subcutaneous Darzalex (daratumumab) and the addition of product sales due to the Antares Pharma acquisition. Revenue for Q2 included $85.3 million in royalties. Adjusted EPS of $0.53 was … Full story available on Benzinga.com
Halozyme Therapeutics: Q2 Earnings Insights 2022/08/10 03:50:59 Benzinga
Halozyme Therapeutics (NASDAQ: HALO ) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Halozyme Therapeutics beat estimated earnings by 6.0%, reporting an EPS of $0.53 versus an estimate of $0.5. Revenue was up $15.91 million from the same period last … Full story available on Benzinga.com
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q2 2022 Results - Earnings Call Transcript 2022/08/09 21:58:01 Seeking Alpha
Halozyme Therapeutics, Inc. (NASDAQ:NASDAQ:HALO) Q2 2022 Earnings Conference Call August 09, 2022 04:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations &…